Pfizer Inc.

NYSE:PFE 주식 리포트

시가총액: US$150.8b

Pfizer 배당 및 자사주 매입

배당 기준 점검 4/6

Pfizer 은(는) 현재 수익률이 6.48% 인 배당금 지급 회사입니다. 다음 지급일은 12th June, 2026 이며 배당락일은 다음과 같습니다. 8th May, 2026.

핵심 정보

6.5%

배당 수익률

n/a

자사주 매입 수익률

총 주주 수익률n/a
미래 배당 수익률6.6%
배당 성장률3.9%
다음 배당 지급일12 Jun 26
배당락일08 May 26
주당 배당금n/a
배당 성향131%

최근 배당 및 자사주 매입 업데이트

Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

Recent updates

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook

Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.

Pfizer: Why You Should Double Down Into Q1

May 01

PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing

Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook

Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade

Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.

PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating

Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.

PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating

Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.

PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares

Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.

PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential

Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.

Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead

Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.

Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating

Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.

PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts

Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Pfizer's Q1 Update May Mark A Bottom In The Stock

Apr 30

Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle

Apr 23

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: PFE 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.

배당금 증가: PFE 의 배당금 지급은 지난 10 년 동안 증가했습니다.

배당 수익률 vs 시장

Pfizer 배당 수익률 vs 시장
PFE의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (PFE)6.5%
시장 하위 25% (US)1.4%
시장 상위 25% (US)4.2%
업계 평균 (Pharmaceuticals)2.2%
분석가 예측 (PFE) (최대 3년)6.6%

주목할만한 배당금: PFE 의 배당금( 6.48% )은 US 시장에서 배당금 지급자의 하위 25%( 1.39% )보다 높습니다.

고배당: PFE 의 배당금( 6.48% )은 US 시장( 4.21% )

주주 대상 이익 배당

수익 보장: 지급 비율 ( 130.8% )이 높기 때문에 PFE 의 배당금 지급은 수익으로 잘 충당되지 않습니다.

주주 현금 배당

현금 흐름 범위: 현금 지급 비율 ( 103.4% )이 높기 때문에 PFE 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/06 04:03
종가2026/05/06 00:00
수익2026/03/29
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Pfizer Inc.는 44명의 분석가가 다루고 있습니다. 이 중 26명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg